<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The tumorigenic potential of the Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>) cell line Akata is dependent on the restricted latency program of Epstein-Barr virus (EBV) that is characteristically maintained in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Within these cells, EBV-mediated inhibition of <z:mpath ids='MPATH_3'>apoptosis</z:mpath> correlates with an up-regulation of BCL-2 levels in concert with a down-regulation in c-MYC expression that occurs under growth-limiting conditions </plain></SENT>
<SENT sid="2" pm="."><plain>Here we addressed whether EBV's effects on <z:mpath ids='MPATH_3'>apoptosis</z:mpath> and tumorigenicity are mediated by the EBV small <z:chebi fb="40" ids="33697">RNAs</z:chebi> EBER-1 and EBER-2 </plain></SENT>
<SENT sid="3" pm="."><plain>Stable expression of the EBERs in EBV-negative Akata <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> cells, at levels comparable to those in EBV-positive cells, significantly enhanced the tumorigenic potential of EBV-negative <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> cells in <z:mp ids='MP_0002536'>SCID</z:mp> mice, but did not fully restore tumorigenicity relative to EBV-positive Akata cells </plain></SENT>
<SENT sid="4" pm="."><plain>Furthermore, <z:mp ids='MP_0002169'>wild-type</z:mp> or greater levels of EBER expression in EBV-negative Akata cells did not promote <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> cell survival </plain></SENT>
<SENT sid="5" pm="."><plain>These data therefore suggest that EBV can contribute to <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> through at least two avenues: an EBER-dependent mechanism that enhances tumorigenic potential independent of a direct effect on <z:mpath ids='MPATH_3'>apoptosis</z:mpath>, and a second mechanism, mediated by an as-yet-unidentified EBV gene(s), that offsets the proapoptotic consequences of deregulated c-MYC in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> </plain></SENT>
</text></document>